A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Phase 3
Completed
- Conditions
- Major Depressive disoder
- Registration Number
- JPRN-jRCT2080221401
- Lead Sponsor
- Eli Lilly Japan K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Male and female ,adult outpatients aged>=18 years
To Meet DSM-IV-TR diagnostic criteria for MDD assessed by the Mini-International Neuropsychiatric Interview (MINI)
Partial response to a course of SSRI treatment and the SSRI treatment must be at a stable
Patients must have a score >=16 on the GRID 17-Item Hamilton Depression Rating Scale (GRID-HAMD17) total score
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method